The polyhydroxy isoflavone 3'-hydroxygenistein (3'-OHG) has a wide range of pharmaceutical and nutraceutical benefits. Therefore, it is important to develop an efficient and sustainable method for 3'-OHG production. Here, we engineered the metabolic pathways of Saccharomyces cerevisiae to achieve de novo biosynthesis of 3'-OHG. First, we screened 2-hydroxyisoflavanone synthase (IFS), cytochrome P450 reductase, and 2-hydroxyisoflavanone dehydratase from different sources and optimized the best combination via promoter engineering. Next, we demonstrated that amplification of the rate-limiting enzyme PlIFS from Pueraria lobata improved genistein production. Increasing the availability of the cofactor heme further increased genistein titer to 44.55 ± 1.82 mg/L. Subsequently, screening and multicopy integration of isoflavone-3'-hydroxylase achieved 13.23 ± 0.27 mg/L 3'-OHG from 100 mg/L naringenin. Finally, 1.40 ± 0.02 mg/L 3'-OHG could be achieved via the de novo biosynthesis pathway. The final strain generated in this study will facilitate the production of polyhydroxy isoflavones via the 3'-OHG biosynthetic pathway.

• PMID: 39948827
• DOI full text
• PubMed
• PubTator

Reference Type

Journal Article

Authors

Tan X, Xiao Z, Zhang S, Wang Y, Zhao Y, Lu Q, Hu F, Zuo S, Mao J, Liu J, ... Show all

Primary Lit For

Additional Lit For

Review For